PRODUCTION OF POTENT NEUTRALIZING POLYCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-CORONAVIRUS-2 (SARS-CoV-2) IN RABBITS, IMMUNIZED WITH RECEPTOR BINDING DOMAIN-HEPATITIS-B SURFACE ANTIGENCONJUGATE PROTEIN AND WHOLE INACTIVATED SARS-CoV-2 (MT416726): A COMPARATIVE STUDY
DOI:
https://doi.org/10.22159/ijap.2025v17i2.52098Keywords:
SARS-CoV-2, ELISA, PRNT50, RBD, Immunization, Polyclonal Antibodies.Abstract
Objective: The current study aims to produce potent neutralizing polyclonal antibodies against novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) by immunization of rabbits.
Methods: Whole inactivated SARS-CoV-2 and purified Receptor Binding Domain-Hepatitis B surface Antigen (RBD-HBsAg) conjugate protein were used as immunogens along with Freud’s incomplete adjuvant for systematic immunization in rabbits by following a protocol approved by the Committee for Control and Supervision of Experiments on Animals (CCSEA) approved Institutional Ethics Committee (IAEC). During the systematic immunization cycle, blood samples were collected periodically after some intervals and checked for in vitro efficacy against SARS-CoV-2 by using Enzyme-Linked Immunosorbent Assay (ELISA) and Plaque Reduction Neutralization Test (PRNT50) methods.
Results: The study revealed that 42 days are required to generate high-neutralizing hyperimmune polyclonal antibodies in rabbits against immunogens. A combination of Freud’s incomplete adjuvant with whole inactivated SARS-CoV-2 and RBD-HBsAg conjugate protein has shown good response in the generation of potent highly specific polyclonal antibodies. RBD-HBsAg Conjugate protein has shown threefold more immunogenicity and neutralizing efficacy as compared to a whole inactivated SARS-CoV-2.
Conclusion: Rabbits immunized with RBD-HBsAg Conjugate protein immunogen generated high neutralizing and more specific polyclonal antibodies. After extensive preclinical and clinical studies, such purified polyclonal antibodies can be used as alternative therapeutic drugs against SARS-CoV-2 infection.
Downloads
References
Yang J, Vaghela S, Yarnoff B, De Boisvilliers S, Di Fusco M, Wiemken TL, Kyaw MH, McLaughlin JM, Nguyen JL. Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical data. Expert Rev. of Vaccines. 2023 Dec 31;22(1):54-65.
Karia R, Gupta I, Khandait H, Yadav A, Yadav A. COVID-19 and its modes of transmission. SN Compr. Clin. Med. 2020 Oct;2(10):1798-801.
Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, Tang X, Carmona Porquera EM, Kalari KR, Kandimalla KK. COVID-19 transmission, current treatment, and future therapeutic strategies. Mol. pharm. 2021 Jan 19;18(3):754-71.
Singh MS, Yellaboina S, Ansari MA. A comprehensive review on the multifaceted interactions between host immunity and viral pathogenesis in COVID-19. Vol. 16, Int. J. Appl. Pharm. Innovare Academics Sciences Pvt. Ltd; 2024; 37–45.
Ansari MZ, Mehta SK, Priyadarshi K, Mohanty B, Sunder A. The Impact of Different Variables on the Three Cell Lines in Cobalamin Deficient Patients in a Tertiary Care Teaching Hospital.Int. J. Pharm. Clin. Res.2024; 16(7); 905-911
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396 (10249):467–78.
Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin. Immunol. 2021 Jan 1;222:108634.
Kaznadzey A, Tutukina M, Bessonova T, Kireeva M, Mazo I. BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19. Front. Immunol. 2022 Apr 13;13:797918.
Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int. J. Surg. 2020 Jun 1;78:185-93..
Behnood SA, Shafran R, Bennett SD, Zhang AXD, O’Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. J. Infect. 2022 Feb 1;84(2):158–70.
Castro Dopico X, Ols S, Loré K, Karlsson Hedestam GB. Immunity to SARS‐CoV‐2 induced by infection or vaccination. J. Int. Med. 2022 Jan;291(1):32-50.
Jahanshahlu L, Rezaei N. Monoclonal antibody as a potential anti-COVID-19. Biomed. Pharmacother. 2020 Sep 1;129:110337.
Rosenstein S, Vaisman‐Mentesh A, Levy L, Kigel A, Dror Y, Wine Y. Production of F (ab′) 2 from Monoclonal and Polyclonal Antibodies. Curr. Protoc. Mol. Biol. 2020 Jun;131(1):e119.
Zheng X, Wong G, Zhao Y, Wang H, He S, Bi Y, Chen W, Jin H, Gai W, Chu D, Cao Z. Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Sci. Report. 2016 Apr 12;6(1):1-7.
Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr. Opin. HIV AIDS. 2015 May 1;10(3):129-34..
Habarugira G, Suen WW, Hobson-Peters J, Hall RA, Bielefeldt-Ohmann H. West Nile virus: an update on pathobiology, epidemiology, diagnostics, control and “one health” implications. Pathogen. 2020 Jul 19;9(7):589.
Hu T, Liu Y, Zhao M, Zhuang Q, Xu L, He Q. A comparison of covid-19, sars and mers. PeerJ. 2020 Aug 19;8:e9725.
Kulkarni R, Patil HP, Palkar S, Lalwani S, Mishra AC, Arankalle V. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA. Journal of Virological Methods. 2021 Jan 1;287:113996.
Barbier M, Lee KS, Vikharankar MS, Rajpathak SN, Kadam N, Wong TY, Russ BP, Cyphert HA, Miller OA, Rader NA, Cooper M. Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2. Frontiers in Immunology. 2022 Aug 15;13:948431..
Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, Shi PY. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nature communications. 2020 Aug 13;11(1):4059.
Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, Yuan M, Leung WS, Chan JM, Chik TS, Choi CY. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. 2020 Apr 23;25(16):2000421.
Deshpande GR, Sapkal GN, Tilekar BN, Yadav PD, Gurav Y, Gaikwad S, et al. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. Ind. J. Med. Res. 2020 Jul 1;152(1):82–7.
Kanne JP, Little BP, Schulte JJ, Haramati A, Haramati LB. Long-term lung abnormalities associated with COVID-19 pneumonia. Radiology. 2022 Aug 30;306(2):e221806.
Assefa N, Hassen JY, Admassu D, Brhane M, Deressa M, Marami D, Teklemariam Z, Dessie Y, Oundo J. COVID-19 testing experience in a resource-limited setting: the use of existing facilities in public health emergency management. Frontiers in Public Health. 2021 Jun 14;9:675553..
Hebbani AV, Pulakuntla S, Pannuru P, Aramgam S, Badri KR, Reddy VD. COVID-19: comprehensive review on mutations and current vaccines. Archives of microbiology. 2022 Jan;204(1):8.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. New Engl. J. Med. 2022 Mar 10;386(10):995–8.
Omolo CA, Soni N, Fasiku VO, Mackraj I, Govender T. Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. Eur J Pharmacol. 2020 Sep 15;883.
Gupta A, Pradhan A, Maurya VK, Kumar S, Theengh A, Puri B, et al. Therapeutic approaches for SARS-CoV-2 infection. Methods. 2021 Nov 1;195:29–43.
Kumar S, Chandele A, Sharma A. Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS pathogens. 2021 Sep 3;17(9):e1009885
Published
How to Cite
Issue
Section
Copyright (c) 2024 DHAIRYASHEEL YADAV, NANDKUMAR KADAM, S. MOHAN KARUPPAYIL, MAYUR VIKHARANKAR, UMESH SHALIGRAM, ASHWINI K. JADHAV
This work is licensed under a Creative Commons Attribution 4.0 International License.
